# Dose-ranging Study to Evaluate the Safety & Immunogenicity of a HIV Vaccine 732461 in Healthy HIV Seronegative Volunteers

> **NCT00434512** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 180 (actual)

## Conditions studied

- AIDS
- HIV Infections

## Interventions

- **BIOLOGICAL:** HIV vaccine 732461

## Key facts

- **NCT ID:** NCT00434512
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02-20
- **Primary completion:** 2008-06-13
- **Final completion:** 2008-06-13
- **Target enrollment:** 180 (ACTUAL)
- **Last updated:** 2019-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00434512

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00434512, "Dose-ranging Study to Evaluate the Safety & Immunogenicity of a HIV Vaccine 732461 in Healthy HIV Seronegative Volunteers". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00434512. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*